Meta-analysisindependent cross-checkabstract checked I-CHM-109 standard review
Can heart damage from anthracyclines be prevented?
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
Overview
de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2
Dexrazoxane cut heart failure in adults by about four-fifths without lowering cancer control.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test a heart-protecting drug
- How was the study done?
Cochrane review of RCTs
- How many people, animals or samples were studied?
13 trials, about 2500 patients
- What was actually found?
Less heart failure in adults
- How large was the observed effect?
RR 0.22
- What do the results mean in everyday life?
Heart damage from chemotherapy can be reduced
- What are the study's limitations?
Weaker evidence in children; possible second-cancer signal
- What does it say about Elawady's specific claim?
Harm is real but manageable
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Not a reason to avoid treatment
Scientific in-depth review
1. Full reference
- Authors
- de Baat EC et al.
- Journal
- Cochrane Database Syst Rev
- Year
- 2022
- Identifier
- PMID 36162822 DOI 10.1002/14651858.CD014638.pub2
- Verification
- verified – PubMed efetch 2026-10-26 (PublicationType and CommentsCorrections checked); Crossref 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Not stated in abstract.
2. Research question
Does dexrazoxane prevent anthracycline cardiotoxicity without reducing anticancer efficacy?
3. Study design and population
- Study design
- Meta-analysis – Cochrane systematic review and meta-analysis of RCTs
- Population
Adults (mostly breast cancer) and children receiving anthracyclines
- Country
International
- Period
Search to May 2021
- Sample size
13 RCTs; 1252 children, 1269 adults
- Inclusion and exclusion criteria
RCTs of dexrazoxane vs placebo/no treatment
4. Methods and endpoints
- Exposure / intervention
Dexrazoxane
- Comparator
Placebo or no additional treatment
- Endpoints
Clinical heart failure, subclinical dysfunction, OS, PFS, tumour response, second malignancies
- Statistical methods
Risk ratios, hazard ratios, GRADE
5. Actual results
- Results
Adults: clinical heart failure RR 0.22 (0.11-0.43; 7 studies, 1221 adults; moderate quality); no difference in OS (HR 1.04, 0.88-1.23) or tumour response (RR 0.91, 0.79-1.04). Children: heart failure RR 0.20 (0.01-4.19; low quality); second malignant neoplasms RR 3.08 (1.13-8.38; low quality).
- Absolute risks
not reported in abstract
- Authors' conclusion
Dexrazoxane prevents or reduces cardiotoxicity in adults without evidence of reduced efficacy; in children it may be associated with more second neoplasms; weigh individually.
6. Strengths
- Cochrane methods with GRADE
- Separate analyses for adults and children
7. Weaknesses
- Heterogeneous outcome definitions
- Low-quality paediatric evidence
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Cochrane review; evidence moderate (adults) to very low (children).
9. Assessment of the statistical interpretation
RR 0.22 (0.11-0.43) is log-symmetric (stats/C-CHM-01.py).
10. Relevance to the specific claim
Shows that anthracycline heart damage is real (it can be measured and partly prevented) and that it can be reduced without giving up the anticancer treatment.
11. Independent contrary findings
None.
12. Transferability to Germany and Europe
Applicable; dexrazoxane is available in Europe.
13. Overall methodological judgement
Moderate-certainty evidence that cardiotoxicity is preventable in adults.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Paediatric second-cancer signal.
15. Linked fact checks
- Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment. – Studies with mixed or unclear results